JP2018518978A5 - - Google Patents

Download PDF

Info

Publication number
JP2018518978A5
JP2018518978A5 JP2017568133A JP2017568133A JP2018518978A5 JP 2018518978 A5 JP2018518978 A5 JP 2018518978A5 JP 2017568133 A JP2017568133 A JP 2017568133A JP 2017568133 A JP2017568133 A JP 2017568133A JP 2018518978 A5 JP2018518978 A5 JP 2018518978A5
Authority
JP
Japan
Prior art keywords
cell according
mil
cell
antigen
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017568133A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018518978A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/041521 external-priority patent/WO2017008019A1/en
Publication of JP2018518978A publication Critical patent/JP2018518978A/ja
Publication of JP2018518978A5 publication Critical patent/JP2018518978A5/ja
Priority to JP2021095119A priority Critical patent/JP2021121230A/ja
Withdrawn legal-status Critical Current

Links

JP2017568133A 2015-07-08 2016-07-08 キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ） Withdrawn JP2018518978A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021095119A JP2021121230A (ja) 2015-07-08 2021-06-07 キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ）

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189928P 2015-07-08 2015-07-08
US62/189,928 2015-07-08
PCT/US2016/041521 WO2017008019A1 (en) 2015-07-08 2016-07-08 Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021095119A Division JP2021121230A (ja) 2015-07-08 2021-06-07 キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ）

Publications (2)

Publication Number Publication Date
JP2018518978A JP2018518978A (ja) 2018-07-19
JP2018518978A5 true JP2018518978A5 (https=) 2019-08-15

Family

ID=57686063

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017568133A Withdrawn JP2018518978A (ja) 2015-07-08 2016-07-08 キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ）
JP2021095119A Pending JP2021121230A (ja) 2015-07-08 2021-06-07 キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ）

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021095119A Pending JP2021121230A (ja) 2015-07-08 2021-06-07 キメラ抗原受容体（ｃａｒ）療法のためのｔ細胞の供給源としての骨髄浸潤リンパ球（ｍｉｌ）

Country Status (12)

Country Link
US (3) US11478548B2 (https=)
EP (1) EP3320087A4 (https=)
JP (2) JP2018518978A (https=)
KR (1) KR20180039068A (https=)
CN (1) CN108026510A (https=)
AU (1) AU2016291199B2 (https=)
CA (1) CA2990694A1 (https=)
HK (2) HK1254313A1 (https=)
IL (1) IL256434B2 (https=)
MA (1) MA42902A (https=)
MX (1) MX2017017083A (https=)
WO (1) WO2017008019A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3320087A4 (en) * 2015-07-08 2019-01-23 The Johns Hopkins University BONE MARROW FILTRATION LYMPHOCYTES (MILS) AS A T-CELL SOURCE FOR CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPY
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US20200224161A1 (en) * 2017-05-10 2020-07-16 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
EP3714041A1 (en) * 2017-11-22 2020-09-30 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
US20190284553A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP3735256A4 (en) 2018-03-22 2021-10-13 Windmil Therapeutics, Inc. BONE MARROW LYMPHOCYTES SPECIFIC TO PROSTATE CANCER AND ASSOCIATED USES
US20210244760A1 (en) * 2018-06-12 2021-08-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptor tumor infiltrating lymphocytes
WO2020004337A1 (ja) * 2018-06-27 2020-01-02 国立大学法人名古屋大学 Ｃｄ３７特異的キメラ抗原レセプター
US20210275589A1 (en) * 2018-07-13 2021-09-09 Nanjing Legend Biotech Co. Ltd. Co-receptor systems for treating infectious diseases
JP2022507113A (ja) * 2018-11-05 2022-01-18 ウィンドミル セラピューティクス インコーポレイテッド クローン性の増大した骨髄浸潤リンパ球およびそれらの使用
SG11202104637VA (en) * 2018-11-30 2021-06-29 Windmil Therapeutics Inc MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY
WO2020198031A1 (en) * 2019-03-22 2020-10-01 Windmil Therapeutics Inc. Lung cancer specific marrow infiltrating lymphocytes and uses thereof
WO2021123832A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
US20230100744A1 (en) * 2020-02-28 2023-03-30 Windmil Therapeutics, Inc. Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils
WO2022066872A1 (en) * 2020-09-24 2022-03-31 Windmil Therapeutics, Inc. Marrow infiltrating lymphocytes (mils) expressing t cell receptors, methods of manufacturing same, and method of using in therapy
US20230372397A1 (en) * 2020-10-06 2023-11-23 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) * 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022098985A1 (en) * 2020-11-05 2022-05-12 Windmil Therapeutics, Inc. Glioblastoma specific marrow infiltrating lymphocytes and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010062742A2 (en) * 2008-11-03 2010-06-03 The Johns Hopkins University Methods for freparation and use of marrow infiltrating lymphocytes (mils)
WO2014085437A2 (en) * 2012-11-27 2014-06-05 The Johns Hopkins University Use of post-transplant cyclophosphamide treated allogeneic marrow infiltrating lymphocytes to augment anti-tumor immunity
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013063419A2 (en) * 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
WO2013109759A1 (en) * 2012-01-17 2013-07-25 Northeastern University Methods and compositions for expanding immunosuppressive t regulatory cells in vitro and uses thereof
KR20150029714A (ko) * 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강
DK2958943T3 (da) * 2013-02-20 2019-12-09 Univ Pennsylvania Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
WO2015092024A2 (en) * 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
US9687510B2 (en) 2014-09-04 2017-06-27 The Johns Hopkins University Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions
CA2991040A1 (en) * 2015-06-29 2017-01-05 The Johns Hopkins University Immune checkpoint chimeric receptors therapy
EP3320087A4 (en) 2015-07-08 2019-01-23 The Johns Hopkins University BONE MARROW FILTRATION LYMPHOCYTES (MILS) AS A T-CELL SOURCE FOR CHIMERIC ANTIGEN RECEPTOR (CAR) THERAPY

Similar Documents

Publication Publication Date Title
JP2018518978A5 (https=)
US11629335B2 (en) Methods of improving vector transduction efficiency into T lymphocytes
JP2020508663A5 (https=)
JP2020504628A5 (https=)
US11806365B2 (en) Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis
JPWO2020132327A5 (https=)
JP2021035366A5 (https=)
AU2014214850C1 (en) Modified T lymphocytes having improved specificity
JP2020515282A5 (https=)
EP3828267A2 (en) Car-t lymphocytes engineered to home to lymph node b cell zone, skin, or gastrointestinal tract
US20210154233A1 (en) MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY
CN108026510A (zh) 作为用于嵌合抗原受体(car)疗法的t细胞来源的骨髓浸润淋巴细胞(mil)
AU2013204923A1 (en) Modified t lymphocytes having improved specificity
WO2025072081A1 (en) Enriched t-cell populations
US20250250348A1 (en) Bispecific Binding Molecules That Target FSHR and CD3
Martin et al. Abstract P4-12-07: Neoadjuvant trastuzumab emtansine and docetaxel, with or without pertuzumab, in patients with HER2-positive early-stage breast cancer: Results from a phase 1b/2a study
Moser et al. Abstract CT170: Trial in progress: A phase 1, first in human clinical trial for T-Plex, a multiplexed, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors
Lee et al. Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine
Rossi et al. Immunological findings in a phase II immunotherapy study using allogeneic lung cancer cells modified to express alpha (1, 3) galactosyltransferase in advanced non-small cell lung cancer (NSCLC)
HK1234782A1 (en) Methods of improving vector transduction efficiency into t lymphocytes
HK1234782B (en) Methods of improving vector transduction efficiency into t lymphocytes
Daisuke et al. Peptide vaccine induces apoptosis of antigen-specific CD8+ T cells
Salazar et al. Abstract P5-16-04: A phase I study of a DNA plasmid based vaccine encoding the HER-2/neu intracellular domain in subjects with HER2+ breast cancer.
NZ712373B2 (en) Modified t lymphocytes
Miyabayashi et al. Cancer stem cells express specific immunogenic proteins that induce Th17-dominant immunity resulting in regression of parental tumor in vivo